stockrow
Friday 6 November 2026
Export ISPC’s income statement to Excel — free account
iSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024.
- Revenue
- −78.7%
- EPS
- +94.2%
- Free cash flow
- −257.7%
Quarter to June 2026, against a year earlier
0.80
0.04
−4.76%
Follow ISPC
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.25 | 1.04 | 2.09 | 7.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.70) | (2.20) | (0.64) | (5.36) | |
P/B ratio |
2.45 | 0.65 | 2.63 | 2.13 | |
Price to Tangible BV |
3.01 | 0.97 | 0.00 | 5.02 | |
EV/Sales |
2.20 | (1.17) | 1.89 | 4.06 | |
EV/EBITDA |
0.00 | 0.31 | 0.00 | 0.00 | |
EV/Operating CF |
(1.07) | 0.53 | (0.30) | (0.27) | |
EV/FCF |
(0.72) | 0.30 | (0.19) | (0.17) | |
Quick Ratio |
0.51 | 1.11 | 0.53 | 0.81 | |
Current Ratio |
0.63 | 1.12 | 0.62 | 0.82 | |
Net Debt/EBITDA |
1.17 | 3.02 | 1.17 | 3.80 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.33 | 0.20 | 0.15 | 0.07 | |
Operating CF/Net income |
0.73 | 0.18 | 1.48 | 0.51 | |
Capex/Depreciation |
(2.18) | 0.00 | (5.15) | 0.00 | |
Research and Development Expense of Revenue |
21.01% | 61.39% | 21.79% | 24.69% | |
Selling, General and Administrative Expense of Revenue |
1,880.86% | 2,799.61% | 1,424.81% | 649.77% | |
Intangible Assets out of Total Assets |
0.06 | 0.10 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.69% | 3.47% | 0.64% | 0.13% | |
Graham Net Nets |
(0.31) | 0.25 | (1.08) | (0.32) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(538.66%) | (867.40%) | (1,090.29%) | (1,986.79%) | |
Free Cash Flow Yield |
(136.38%) | (370.41%) | (483.07%) | (293.81%) | |
Revenue per Share |
0.73 | 0.27 | 0.46 | 0.11 | |
Operating CF per Share |
(13.94) | (4.73) | (9.85) | (0.49) | |
Capex per Share |
(6.85) | 0.00 | (2.05) | 0.00 | |
Free Cash Flow per Share |
(20.79) | (4.73) | (11.90) | (0.49) | |
Cash per Share |
19.06 | 35.51 | 8.26 | 3.17 | |
Shareholders Equity per Share |
21.05 | 15.94 | 2.38 | 1.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.05 | 15.94 | 2.38 | 1.25 | |
Free Cash Flow |
(3.04) | (0.92) | (4.06) | (0.69) | |
Working Capital |
(2.10) | 0.72 | (2.12) | (0.99) | |
Capital Expenditures |
(1.00) | 0.00 | (0.70) | 0.00 | |
Net Current Asset Value |
(2.32) | 0.51 | (2.31) | (1.17) | |
EV/EBIT |
0.00 | 0.25 | 0.00 | 0.00 | |
Capex to Sales |
9.38 | 0.00 | 4.49 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.37 | 0.75 | 0.36 | 0.20 | |
Average Payables |
4.41 | 4.78 | 4.25 | 4.49 | |
Average Assets |
10.13 | 9.44 | 6.73 | 6.71 | |
Average Common Equity |
3.89 | 3.20 | 1.24 | 1.18 |
Columns are period end dates · fundamentals updated 26 Oct 2026